16
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      A 7-Year Brazilian National Perspective on Plasmid-Mediated Carbapenem Resistance in Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii Complex and the Impact of the Coronavirus Disease 2019 Pandemic on Their Occurrence

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Carbapenemase production is a global public health threat. Antimicrobial resistance (AMR) data analysis is critical to public health policy. Here we analyzed carbapenemase detection trends using the AMR Brazilian Surveillance Network.

          Methods

          Carbapenemase detection data from Brazilian hospitals included in the public laboratory information system dataset were evaluated. The detection rate (DR) was defined as carbapenemase detected by gene tested per isolate per year. The temporal trends were estimated using the Prais–Winsten regression model. The impact of COVID-19 on carbapenemase genes in Brazil was determined for the period 2015–2022. Detection pre- (October 2017 to March 2020) and post-pandemic onset (April 2020 to September 2022) was compared using the χ 2 test. Analyses were performed with Stata 17.0 (StataCorp, College Station, TX).

          Results

          83 282 bla KPC and 86 038 bla NDM were tested for all microorganisms. Enterobacterales DR for bla KPC and bla NDM was 68.6% (41 301/60 205) and 14.4% (8377/58 172), respectively. P. aeruginosa DR for bla NDM was 2.5% (313/12 528). An annual percent increase for bla NDM of 41.1% was observed, and a decrease for bla KPC of −4.0% in Enterobacterales, and an annual increase for bla NDM of 71.6% and for bla KPC of 22.2% in P. aeruginosa. From 2020 to 2022, overall increases of 65.2% for Enterobacterales, 77.7% for ABC, and 61.3% for P. aeruginosa were observed in the total isolates.

          Conclusions

          This study shows the strengths of the AMR Brazilian Surveillance Network with robust data related to carbapenemases in Brazil and the impact of COVID-19 with a change in carbapenemase profiles with bla NDM rising over the years.

          Abstract

          Seven-year surveillance in Brazil showed a >60% increase in resistance genes during the COVID-19 pandemic, especially bla NDM in Enterobacterales and Pseudomonas aeruginosa. bla KPC in Enterobacterales and bla SPM in P. aeruginosa decreased. These data contribute to Antimicrobial Resistance public policies.

          Related collections

          Most cited references38

          • Record: found
          • Abstract: found
          • Article: not found

          Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

          Summary Background An ongoing outbreak of pneumonia associated with the severe acute respiratory coronavirus 2 (SARS-CoV-2) started in December, 2019, in Wuhan, China. Information about critically ill patients with SARS-CoV-2 infection is scarce. We aimed to describe the clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia. Methods In this single-centered, retrospective, observational study, we enrolled 52 critically ill adult patients with SARS-CoV-2 pneumonia who were admitted to the intensive care unit (ICU) of Wuhan Jin Yin-tan hospital (Wuhan, China) between late December, 2019, and Jan 26, 2020. Demographic data, symptoms, laboratory values, comorbidities, treatments, and clinical outcomes were all collected. Data were compared between survivors and non-survivors. The primary outcome was 28-day mortality, as of Feb 9, 2020. Secondary outcomes included incidence of SARS-CoV-2-related acute respiratory distress syndrome (ARDS) and the proportion of patients requiring mechanical ventilation. Findings Of 710 patients with SARS-CoV-2 pneumonia, 52 critically ill adult patients were included. The mean age of the 52 patients was 59·7 (SD 13·3) years, 35 (67%) were men, 21 (40%) had chronic illness, 51 (98%) had fever. 32 (61·5%) patients had died at 28 days, and the median duration from admission to the intensive care unit (ICU) to death was 7 (IQR 3–11) days for non-survivors. Compared with survivors, non-survivors were older (64·6 years [11·2] vs 51·9 years [12·9]), more likely to develop ARDS (26 [81%] patients vs 9 [45%] patients), and more likely to receive mechanical ventilation (30 [94%] patients vs 7 [35%] patients), either invasively or non-invasively. Most patients had organ function damage, including 35 (67%) with ARDS, 15 (29%) with acute kidney injury, 12 (23%) with cardiac injury, 15 (29%) with liver dysfunction, and one (2%) with pneumothorax. 37 (71%) patients required mechanical ventilation. Hospital-acquired infection occurred in seven (13·5%) patients. Interpretation The mortality of critically ill patients with SARS-CoV-2 pneumonia is considerable. The survival time of the non-survivors is likely to be within 1–2 weeks after ICU admission. Older patients (>65 years) with comorbidities and ARDS are at increased risk of death. The severity of SARS-CoV-2 pneumonia poses great strain on critical care resources in hospitals, especially if they are not adequately staffed or resourced. Funding None.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing

            Abstract Background To explore and describe the current literature surrounding bacterial/fungal co-infection in patients with coronavirus infection. Methods MEDLINE, EMBASE, and Web of Science were searched using broad based search criteria relating to coronavirus and bacterial co-infection. Articles presenting clinical data for patients with coronavirus infection (defined as SARS-1, MERS, SARS-COV-2, and other coronavirus) and bacterial/fungal co-infection reported in English, Mandarin, or Italian were included. Data describing bacterial/fungal co-infections, treatments, and outcomes were extracted. Secondary analysis of studies reporting antimicrobial prescribing in SARS-COV-2 even in the absence of co-infection was performed. Results 1007 abstracts were identified. Eighteen full texts reported bacterial/fungal co-infection were included. Most studies did not identify or report bacterial/fungal coinfection (85/140;61%). 9/18 (50%) studies reported on COVID-19, 5/18 (28%) SARS-1, 1/18 (6%) MERS, and 3/18 (17%) other coronavirus. For COVID-19, 62/806 (8%) patients were reported as experiencing bacterial/fungal co-infection during hospital admission. Secondary analysis demonstrated wide use of broad-spectrum antibacterials, despite a paucity of evidence for bacterial coinfection. On secondary analysis, 1450/2010 (72%) of patients reported received antimicrobial therapy. No antimicrobial stewardship interventions were described. For non-COVID-19 cases bacterial/fungal co-infection was reported in 89/815 (11%) of patients. Broad-spectrum antibiotic use was reported. Conclusions Despite frequent prescription of broad-spectrum empirical antimicrobials in patients with coronavirus associated respiratory infections, there is a paucity of data to support the association with respiratory bacterial/fungal co-infection. Generation of prospective evidence to support development of antimicrobial policy and appropriate stewardship interventions specific for the COVID-19 pandemic are urgently required.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Carbapenem resistance: overview of the problem and future perspectives.

              Carbapenem resistance, mainly among Gram-negative pathogens, is an ongoing public-health problem of global dimensions. This type of antimicrobial resistance, especially when mediated by transferable carbapenemase-encoding genes, is spreading rapidly causing serious outbreaks and dramatically limiting treatment options. In this article, important key points related to carbapenem resistance are reviewed and future perspectives are discussed.
                Bookmark

                Author and article information

                Contributors
                Journal
                Clin Infect Dis
                Clin Infect Dis
                cid
                Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
                Oxford University Press (US )
                1058-4838
                1537-6591
                01 July 2023
                05 July 2023
                05 July 2023
                : 77
                : Suppl 1 , The Evolving Challenges of Antibiotic Resistance in Low- and Middle-Income Countries: Priorities and Solutions
                : S29-S37
                Affiliations
                Escola Paulista de Medicina (EPM), Universidade Federal de São Paulo—UNIFESP , São Paulo, Brazil
                Infectious Diseases Discipline, Laboratório Especial de Microbiologia Clínica—LEMC/ALERTA, EPM, UNIFESP , São Paulo, Brazil
                Escola Paulista de Medicina (EPM), Universidade Federal de São Paulo—UNIFESP , São Paulo, Brazil
                Infectious Diseases Discipline, Laboratório Especial de Microbiologia Clínica—LEMC/ALERTA, EPM, UNIFESP , São Paulo, Brazil
                Escola Paulista de Medicina (EPM), Universidade Federal de São Paulo—UNIFESP , São Paulo, Brazil
                Escola Paulista de Medicina (EPM), Universidade Federal de São Paulo—UNIFESP , São Paulo, Brazil
                Escola Paulista de Medicina (EPM), Universidade Federal de São Paulo—UNIFESP , São Paulo, Brazil
                Laboratorio Central do Paraná - LACENPR, Secretaria de Estado da Saúde , Curitiba, Parana, Brazil
                Escola de Medicina e Ciencias da Vida - EMCV, Pontifícia Universidade Católica do Paraná—PUCPR , Curitiba, Parana, Brazil
                Laboratorio Central do Paraná - LACENPR, Secretaria de Estado da Saúde , Curitiba, Parana, Brazil
                Escola de Medicina e Ciencias da Vida - EMCV, Pontifícia Universidade Católica do Paraná—PUCPR , Curitiba, Parana, Brazil
                Instituto Oswaldo Cruz (IOC)—Fundação Instituto Oswaldo Cruz (FIOCRUZ) , Rio de Janeiro, Brazil
                Laboratório de Pesquisa em Infecção Hospitalar—LAPIH, Instituto Oswaldo Cruz , Rio de Janeiro, Brazil
                Instituto Oswaldo Cruz (IOC)—Fundação Instituto Oswaldo Cruz (FIOCRUZ) , Rio de Janeiro, Brazil
                Laboratório de Pesquisa em Infecção Hospitalar—LAPIH, Instituto Oswaldo Cruz , Rio de Janeiro, Brazil
                Instituto Oswaldo Cruz (IOC)—Fundação Instituto Oswaldo Cruz (FIOCRUZ) , Rio de Janeiro, Brazil
                Laboratório de Pesquisa em Infecção Hospitalar—LAPIH, Instituto Oswaldo Cruz , Rio de Janeiro, Brazil
                Coordenação Geral de Laboratórios de Saúde Publica, Departamento de Articulação Estratégica de Vigilância em Saúde e Ambiente, Secretaria de Vigilância em Saúde e Ambiente, Ministério da Saúde , Brasilia, Distrito Federal, Brazil
                Núcleo de Epidemiologia e Vigilância em Saúde, Instituto Oswaldo Cruz—FIOCRUZ , Brasilia, Distrito Federal, Brazil
                Coordenação Geral de Laboratórios de Saúde Publica, Departamento de Articulação Estratégica de Vigilância em Saúde e Ambiente, Secretaria de Vigilância em Saúde e Ambiente, Ministério da Saúde , Brasilia, Distrito Federal, Brazil
                Instituto Oswaldo Cruz (IOC)—Fundação Instituto Oswaldo Cruz (FIOCRUZ) , Rio de Janeiro, Brazil
                Laboratório de Pesquisa em Infecção Hospitalar—LAPIH, Instituto Oswaldo Cruz , Rio de Janeiro, Brazil
                Laboratorio Central do Paraná - LACENPR, Secretaria de Estado da Saúde , Curitiba, Parana, Brazil
                Escola de Medicina e Ciencias da Vida - EMCV, Pontifícia Universidade Católica do Paraná—PUCPR , Curitiba, Parana, Brazil
                Author notes

                A. P. D. C.-A. and M. P. are senior authors and contributed equally to this work.

                Correspondence: M. Pillonetto, Setor de Bacteriologia, Laboratorio Central do Paraná - LACENPR, Secretaria de Estado da Saúde-SESA, Curitiba, Parana, Brazil ( mpilonetto@ 123456sesa.pr.gov.br ).

                Potential conflicts of interest. B. R. S. K., I. C. D. O. S., C. M. R. D. S., and A. P. D. C. A. report funding from the CDC, Brazilian Ministry of Health, Agência Nacional de Vigilância Sanitária (ANVISA), and Fundação Oswaldo Cruz; payments to their laboratory (LAPIH) from the CDC, ANVISA, Fundação Oswaldo Cruz, and Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro. M. P. reports funding support from the Instituto Oswaldo Cruz, Coordenação Geral de Laboratórios de Saúde Publica do Ministério da Saúde, and the CDC; payment for a training lecture from Pfizer; and holding an unpaid position on the Brazilian Committee on Antimicrobial Susceptibility Testing. A. L. D. A. reports funding from the Instituto Oswaldo Cruz Brasilia and Coordenação Geral de Laboratórios de Saúde Publica do Ministério da Saúde. R. T. D. S. P. reports funding from the Instituto Oswaldo Cruz, Coordenação Geral de Laboratórios de Saúde Publica do Ministério da Saúde, Agência Nacional de Vigilância Sanitária, and the CDC and participation on a data and safety monitoring or advisory board for Global Leaders Group and the World Health Organization Global AMR research agenda in human health. All other authors report no potential conflicts.

                All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

                Author information
                https://orcid.org/0000-0003-2896-3186
                Article
                ciad260
                10.1093/cid/ciad260
                10321697
                37406041
                1d7518d1-03f1-4138-9eb9-c7ed190566dc
                © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

                This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                Page count
                Pages: 9
                Funding
                Funded by: Centers for Diseases Control and Prevention, DOI 10.13039/100000030;
                Funded by: (CDC;;
                Award ID: CDC-RFA-CK21-2104
                Categories
                Supplement Article
                AcademicSubjects/MED00290

                Infectious disease & Microbiology
                carbapenemases,covid-19, bla ndm , bla kpc , bla oxa-23
                Infectious disease & Microbiology
                carbapenemases, covid-19, bla ndm , bla kpc , bla oxa-23

                Comments

                Comment on this article